000057090 001__ 57090
000057090 005__ 20200221144219.0
000057090 0247_ $$2doi$$a10.1371/journal.pone.0161574
000057090 0248_ $$2sideral$$a96648
000057090 037__ $$aART-2016-96648
000057090 041__ $$aeng
000057090 100__ $$0(orcid)0000-0001-6258-2489$$aGarcia-Martin, E.$$uUniversidad de Zaragoza
000057090 245__ $$aFibromyalgia is correlated with retinal nerve fiber layer thinning
000057090 260__ $$c2016
000057090 5060_ $$aAccess copy available to the general public$$fUnrestricted
000057090 5203_ $$aObjective To investigate whether fibromyalgia induces axonal damage in the optic nerve that can be detected using optical coherence tomography (OCT), as the retinal nerve fiber layer (RNFL) is atrophied in patients with fibromyalgia compared with controls. Methods Fibromyalgia patients (n = 116) and age-matched healthy controls (n = 144) were included in this observational and prospective cohort study. All subjects underwent visual acuity measurement and structural analysis of the RNFL using two OCT devices (Cirrus and Spectralis). Fibromyalgia patients were evaluated according to Giesecke''s fibromyalgia subgroups, the Fibromyalgia Impact Questionnaire (FIQ), and the European Quality of Life-5 Dimensions (EQ5D) scale. We compared the differences between fibromyalgia patients and controls, and analyzed the correlations between OCT measurements, disease duration, fibromyalgia subgroups, severity, and quality of life. The impact on quality of life in fibromyalgia subgroups and in patients with different disease severity was also analyzed. Results A significant decrease in the RNFL was detected in fibromyalgia patients compared with controls using the two OCT devices: Cirrus OCT ganglion cell layer analysis registered a significant decrease in the minimum thickness of the inner plexiform layer (74.99±16.63 vs 79.36±3.38 um, respectively; p = 0.023), nasal inferior, temporal inferior and temporal superior sectors (p = 0.040; 0.011 and 0.046 respectively). The Glaucoma application of the Spectralis OCT revealed thinning in the nasal, temporal inferior and temporal superior sectors (p = 0.009, 0.006, and 0.002 respectively) of fibromyalgia patients and the Axonal application in all sectors, except the nasal superior and temporal sectors. The odds ratio (OR) to estimate the size effect of FM in RNFL thickness was 1.39. RNFL atrophy was detected in patients with FIQ scores 60) compared with patients with mild fibromyalgia (FIQ<60; 145.85±24.32 vs 138.99±18.09 um, respectively; 145.43±13.21 vs 139.85±13.09 um, p = 0.032 with the Glaucoma application and p = 0.021 with the Axonal application). The subgroup with biologic fibromyalgia exhibited significant thinning in the temporal inferior and superior sectors (115.17±20.82 um and 117.05 ±24.19 um, respectively) compared with the depressive (130.83±22.97 um and 127.71 ±26.10 um, respectively) and atypical (128.60±26.54 um and 125.55±23.65 um, respectively) subgroups (p = 0.005 and 0.001 respectively). Conclusions Fibromyalgia causes subclinical axonal damage in the RNFL that can be detected using innocuous and non-invasive OCT, even in the early disease stages. The impact on the RNFL in the temporal sectors is greater in patients with biologic fibromyalgia, suggesting the presence of neurodegenerative processes in this subgroup of patients with fibromyalgia.
000057090 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000057090 590__ $$a2.806$$b2016
000057090 591__ $$aMULTIDISCIPLINARY SCIENCES$$b15 / 63 = 0.238$$c2016$$dQ1$$eT1
000057090 592__ $$a1.236$$b2016
000057090 593__ $$aAgricultural and Biological Sciences (miscellaneous)$$c2016$$dQ1
000057090 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000057090 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2016$$dQ1
000057090 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000057090 700__ $$0(orcid)0000-0002-3797-4218$$aGarcia-Campayo, J.$$uUniversidad de Zaragoza
000057090 700__ $$aPuebla-Guedea, M.
000057090 700__ $$0(orcid)0000-0001-9876-5850$$aAscaso, F.J.$$uUniversidad de Zaragoza
000057090 700__ $$aRoca, M.
000057090 700__ $$aGutierrez-Ruiz, F.
000057090 700__ $$aVilades, E.
000057090 700__ $$0(orcid)0000-0002-1402-3129$$aPolo, V.$$uUniversidad de Zaragoza
000057090 700__ $$0(orcid)0000-0002-6745-7668$$aLarrosa, J.M.$$uUniversidad de Zaragoza
000057090 700__ $$0(orcid)0000-0003-2389-8282$$aPablo, L.E.$$uUniversidad de Zaragoza
000057090 700__ $$aSatue, M.
000057090 7102_ $$11004$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Oftalmología
000057090 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000057090 773__ $$g11, 9 (2016), 0161574 [15 pp]$$pPLoS One$$tPloS one$$x1932-6203
000057090 8564_ $$s3092609$$uhttps://zaguan.unizar.es/record/57090/files/texto_completo.pdf$$yVersión publicada
000057090 8564_ $$s99684$$uhttps://zaguan.unizar.es/record/57090/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000057090 909CO $$ooai:zaguan.unizar.es:57090$$particulos$$pdriver
000057090 951__ $$a2020-02-21-13:14:05
000057090 980__ $$aARTICLE